Cerevasc has announced that data on its minimally invasive central nervous system (CNS) delivery system will be presented for the first time at the American Society of Gene and Cell Therapy annual meeting (16–20 May 2023, Los Angeles, USA).
The data in question will be delivered on Wednesday 17 May, at 12:00 PST, in a poster session (abstract number 375), as per a press release from the company.
“We are excited to share the results of our in vivo investigation using the eShunt platform to deliver gene therapy to the CNS,” said Dan Levangie, chairman and CEO of Cerevasc.
“The gene and cell therapy community has made tremendous progress in bringing life-changing therapies to patients, but the route of administration for CNS focused therapies can be an obstacle to clinical success. We believe our novel approach has the potential to provide the community an attractive solution to common CNS delivery challenges.”